Genscript Biotech Corporation (01548) published its monthly return for the equity issuer for January 2026 on 3 February 2026. The authorized share capital remained at 5,000,000,000 ordinary shares, each with a par value of USD 0.001, totaling USD 5,000,000.

The issued share count (excluding treasury shares) increased by 140,000 compared to the prior month, resulting in a closing balance of 2,186,518,520 issued shares. The new shares were issued through the Post-IPO Share Option Scheme, raising HKD 336,840 in total. The company confirmed that its public float level continues to meet the 25% requirement.